To view this content, Javascript must be enabled and you need the latest Adobe Flash Player.
Download the free Flash Player now.
Results from the pivotal 2-year study showed that physical disability was slowed by 37% in a 2-year period (p=0.02).3,a
FDA-approved labeling includes up to 3 years of clinical data.
R. Phillip Kinkel, MD Discusses How the CHAMPIONS Study has Affected the Treatment of MS
To view this content, Javascript must be enabled and you need the latest Adobe Flash Player.
Download the free Flash Player now.
Footnotes
a Based on a 2-year pivotal trial (N=301) using an endpoint criterion of ≤1.0 increase in EDSS score sustained for 6 months.
- Biogen Idec, internal data on file.
- CHAMPIONS Study Group. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006;66:1-7.
- Jacobs LD, Cookfair DL, Rudick RA, et al; and The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294.
